Clinical Trial Update: sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a secretory phospholipase A2 (sPLA2) inhibitor to reduce enzyme release after percutaneous coronary intervention in patients with cor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• sPLA2 inhibitor (unspecified)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED